Immuneering (IMRX) Equity Average (2020 - 2024)
Immuneering has reported Equity Average over the past 5 years, most recently at $62.0 million for Q3 2024.
- Quarterly results put Equity Average at $62.0 million for Q3 2024, down 43.4% from a year ago — trailing twelve months through Sep 2024 was $62.0 million (down 43.4% YoY), and the annual figure for FY2023 was $100.2 million, down 24.6%.
- Equity Average for Q3 2024 was $62.0 million at Immuneering, down from $72.5 million in the prior quarter.
- Over the last five years, Equity Average for IMRX hit a ceiling of $157.1 million in Q4 2021 and a floor of -$31.9 million in Q2 2021.
- Median Equity Average over the past 5 years was $97.3 million (2023), compared with a mean of $76.2 million.
- Biggest five-year swings in Equity Average: soared 898.79% in 2021 and later crashed 43.4% in 2024.
- Immuneering's Equity Average stood at -$19.7 million in 2020, then soared by 898.79% to $157.1 million in 2021, then fell by 26.26% to $115.9 million in 2022, then fell by 16.03% to $97.3 million in 2023, then plummeted by 36.26% to $62.0 million in 2024.
- The last three reported values for Equity Average were $62.0 million (Q3 2024), $72.5 million (Q2 2024), and $84.6 million (Q1 2024) per Business Quant data.